Similarly, also in agreement with observations in clinical trials [51, 67], the present model showed limited or no activity when TNBC tumor line MC1 was treated with an anti-CTLA-4 antibody, further validating the humanized mouse model because it reproduces some of the most relevant results observed during the clinical evaluation of immune CPIs. This evidence concerns the gene CTLA4 and neoplasm.